AI-Powered Liver Tumor Ablation Software Leverages CT, MRI and Ultrasound for Real-Time Image Guidance


Through the use of artificial intelligence (AI) and imaging modalities such as ultrasound, CT, and MRI, the newly FDA-cleared VisAble.IO software reportedly enhances planning and real-time assessment for liver tumor ablation procedures.

The Food and Drug Administration (FDA) has granted 510(k) clearance for VisAble.IO (TechsoMed), an artificial intelligence (AI)-enabled software that may facilitate improved real-time imaging guidance — through ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI) — for liver tumor ablation procedures.

TechsoMed said the software’s advanced computation and image registration elevate the planning and real-time assessment of liver tumor ablation.

The company noted that key benefits of the VisAble.IO software include:

• three-dimensional (3D) anatomical views of ablation targets;

• overlay positioning of virtual instruments and ablation region estimates onto imaging; and

• immediate post-procedure 3D views to assess ablation margins and potentially missed volumes.

“There is a real need for a good and efficient assessment tool, and (VisAble.IO) can serve any physician performing thermal ablations,” noted Ryosuke Tateishi, M.D., Ph.D., an associate professor in the Department of Gastroenterology at the University of Tokyo.

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2023 MJH Life Sciences

All rights reserved.